OBJECTIVE: To investigate the association between polymorphisms in the human CYP2A6 gene, CYP2A6 enzyme activity and the influence of cigarette smoking in a Thai population. METHODS: Coumarin (5 mg capsule) was administered to 194 healthy Thai subjects. Genetic variation of the CYP2A6 gene was identified using PCR methods. The excreted dose of 7-hydroxycoumarin (as a percentage of the urine concentration) 2 h after administration was calculated as an index of coumarin metabolism. RESULTS: The frequencies of CYP2A6 alleles *1A, *1B, *4C, *7, *8, *9 and *10 were 34.0, 35.3, 9.3, 6.4, 0.5, 12.1 and 2.4%, respectively. Of the 194 subjects tested, the number (percentages) of Thai participants classified as ultra-rapid, extensive, intermediate and poor metabolizers were 8 (4.1%), 159 (82.0%) 22 (11.3%) and five (2.6%), respectively. CONCLUSION: A relationship between the interindividual differences in coumarin metabolism and genetic polymorphisms of the CYP2A6 gene was observed.
OBJECTIVE: To investigate the association between polymorphisms in the humanCYP2A6 gene, CYP2A6 enzyme activity and the influence of cigarette smoking in a Thai population. METHODS:Coumarin (5 mg capsule) was administered to 194 healthy Thai subjects. Genetic variation of the CYP2A6 gene was identified using PCR methods. The excreted dose of 7-hydroxycoumarin (as a percentage of the urine concentration) 2 h after administration was calculated as an index of coumarin metabolism. RESULTS: The frequencies of CYP2A6 alleles *1A, *1B, *4C, *7, *8, *9 and *10 were 34.0, 35.3, 9.3, 6.4, 0.5, 12.1 and 2.4%, respectively. Of the 194 subjects tested, the number (percentages) of Thai participants classified as ultra-rapid, extensive, intermediate and poor metabolizers were 8 (4.1%), 159 (82.0%) 22 (11.3%) and five (2.6%), respectively. CONCLUSION: A relationship between the interindividual differences in coumarin metabolism and genetic polymorphisms of the CYP2A6 gene was observed.
Authors: M Oscarson; R A McLellan; H Gullstén; Q Y Yue; M A Lang; M L Bernal; B Sinues; A Hirvonen; H Raunio; O Pelkonen; M Ingelman-Sundberg Journal: FEBS Lett Date: 1999-04-01 Impact factor: 4.124
Authors: M Nakajima; J T Kwon; N Tanaka; T Zenta; Y Yamamoto; H Yamamoto; H Yamazaki; T Yamamoto; Y Kuroiwa; T Yokoi Journal: Clin Pharmacol Ther Date: 2001-01 Impact factor: 6.875